Dutasteride's market share is on the rise

200 million won in 2018 → 9.1 billion won in sales in 2022

10% growth in market dominance

GSK encapsulated Avodart's undisputed number one

Tablet-type dutasteride (left) from JW Pharmaceutical Co., Ltd.

 

and Avodart, a capsule-type product from GSK

The biggest advantage of solving the leakage problem is caused by the soft capsule shell rupture.

 

In the dutasteride drug market, which has been growing mainly in capsule form, recently launched tablet-type products are gradually increasing sales.

 

Based on UBIST, dutasteride tablets generated sales of 9.1 billion won last year from 200 million won in 2018, accounting for 10% of the total market.

 

Dutasteride capsules posted sales of 82.9 billion won last year from 55.9 billion won in 2018.

 

Over the past five years (2018-2022), the performance was 55.9 billion, 68.3 billion, 74.7 billion, 80.7 billion, and 82.9 billion won.

 

During the same period, refining shows the growth of 200 million, 3.1 billion, 5 billion, 7.2 billion, and 9.1 billion won.

 

The Dutasteride capsule-type leading product is ranked No.

 

1 in the related field as GSK Avodart.

 

Based on drug distribution performance, the sales of these drugs last year were around 43.7 billion won.

 

The growth rate from 2021 to 2022 is showing an increase of 4%.

 

Damodat of Hyundai Pharm, Adamo of Hanall Biopharma, and Jdart of JW Pharmaceutical posted sales of 1.4 billion won, 1.1 billion won, and 1 billion won, respectively, last year.

 

Dutasteride (tablet type) has 28 products on the market, and JW Pharmaceutical produces 83% of them through CMO.

 

A total of three domestic companies, including JW Pharmaceutical, have dutasteride tablet manufacturing technology.

 

Avodart, a prostatic hyperplasia treatment developed by GSK in 1993, is the first product.

 

GSK started selling Avodart in 2001 after receiving US FDA approval and conducted clinical trials in Korea in 2006, and in 2009, it was approved for hair loss by the Korean Food and Drug Administration for the first time in the world.

 

As the patent expired in 2016, many generics have been released.

 

Dutasteride is a drug with a mechanism of reducing dihydrotestosterone converted by 5α-reductase.

 

Due to the nature of dutasteride being insoluble in water, it is difficult to make it into a tablet form, so all generics, including the original Avodart, have been sold as soft capsules.

 

In November 2018, JW Pharmaceutical launched Jdart, a purified product for the first time in Korea.

 

Recently, it succeeded in obtaining a patent for dutasteride tablet manufacturing technology (the second in the world after an Indian pharmaceutical company) from the Korean Intellectual Property Office.

 

The JW Pharmaceutical Research Center has succeeded in developing dutasteride into a tablet formulation by applying the Self micro-emulsifying drug delivery system.

 

The tablet type improved the convenience of patients taking the soft capsule by improving the discomfort of sticking to the mouth and esophagus when taking the soft capsule and also solved the problem of content leakage due to the rupture of the soft capsule shell.